Protagonist Therapeutics (PTGX, Financial) announced a first-quarter revenue of $28.32 million, falling short of the anticipated $30.44 million. Despite this, the company has experienced significant advancements in early 2025, particularly with its late-stage partnered assets, rusfertide and icotrokinra. Both drugs are on track to submit NDA filings by the end of the year.
Protagonist's leadership is excited about presenting data from the Phase 3 VERIFY study of rusfertide at a major conference on June 1st. Additionally, the successful Phase 2b ANTHEM study of icotrokinra in ulcerative colitis paves the way for further research in treating both UC and Crohn’s disease.
The company is also focusing on the progression of pre-clinical candidates, notably the oral IL-17 antagonist PN-881, alongside drugs from their anti-obesity and hepcidin programs. Thanks to a solid cash position, Protagonist is poised to independently advance these early-stage programs into pivotal clinical studies, starting with PN-881 in 2025.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 9 analysts, the average target price for Protagonist Therapeutics Inc (PTGX, Financial) is $69.44 with a high estimate of $82.00 and a low estimate of $45.00. The average target implies an upside of 65.30% from the current price of $42.01. More detailed estimate data can be found on the Protagonist Therapeutics Inc (PTGX) Forecast page.
Based on the consensus recommendation from 10 brokerage firms, Protagonist Therapeutics Inc's (PTGX, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Protagonist Therapeutics Inc (PTGX, Financial) in one year is $91.53, suggesting a upside of 117.88% from the current price of $42.01. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Protagonist Therapeutics Inc (PTGX) Summary page.
